How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,287 results for

"covid 19" OR "novel coronavirus" OR "SARS-CoV-2" OR "2019-nCoV" OR "2019nCoV"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries Full Text available with Trip Pro

The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries by Michael C. Grant, Luke Geoghegan, Marc Arbyn, Zakaria Mohammed, Luke McGuinness, Emily L. Clarke, Ryckie Wade :: SSRN Share: Permalink Using these links (...) of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries 63 Pages Posted: 1 Jun 2020 University of Sheffield Imperial College London - Department of Surgery and Cancer Sciensano University of Leeds - Leeds Institute for Medical Research University of Bristol - Department of Population Health Sciences University of Leeds - Division of Pathology and Data Analytics Leeds Teaching Hospitals Trust, Department

2020 SSRN Electronic Journal

2. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Full Text available with Trip Pro

Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. The year 2020 has seen a major and sustained outbreak of a novel betacoronavirus (severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2) infection that causes fever, severe respiratory illness and pneumonia, a disease called COVID-19. At the time of writing, the death toll was greater than 120 000 worldwide with more than 2 million documented infections. The genome of the CoV encodes a number of structural (...) proteins that facilitate cellular entry and assembly of virions, of which the spike protein S appears to be critical for cellular entry. The spike protein guides the virus to attach to the host cell. The spike protein contains a receptor-binding domain (RBD), a fusion domain and a transmembrane domain. The RBD of spike protein S binds to Angiotensin Converting Enzyme 2 (ACE2) to initiate cellular entry. The spike protein of SARS-CoV-2 shows more than 90% amino acid similarity to the pangolin and bat

2020 Journal of Clinical Pathology

3. COVID-19 - SARS-CoV-2

COVID-19 - SARS-CoV-2 1 Chapter 14a - COVID-19 - SARS-Cov-2 Chapter 14a - COVID-19 - SARS-CoV-2 12 February 2021 14a COVID-19 - SARS-CoV-2 NOTIFIABLE The virus COVID-19 disease first emerged as a presentation of severe respiratory infection in Wuhan, China in late 2019 (WHO, 2020). By January 2020, lower respiratory samples taken from affected patients were sequenced and demonstrated a novel coronavirus (SARS-CoV-2) (Huang et al, 2020). The first two cases in the UK were seen in late January (...) transmission is maximal in the first week of illness. Symptomatic and pre-symptomatic transmission (1-2 days before symptom onset), is thought to play a greater role in the spread of SARS-CoV-2 than asymptomatic transmission.2 Chapter 14a - COVID-19 - SARS-Cov-2 Chapter 14a - COVID-19 - SARS-CoV-2 12 February 2021 The disease In adults, the clinical picture varies widely. A significant proportion of individuals are likely to have mild symptoms and may be asymptomatic at the time of diagnosis. Symptoms

2021 The Green Book

4. mRNA-1273 SARS-CoV-2 - Moderna Covid-19 vaccine

mRNA-1273 SARS-CoV-2 - Moderna Covid-19 vaccine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2021 Health Canada - Drug and Health Product Register

5. COVID-19: investigation and management of suspected SARS-CoV-2 reinfections

COVID-19: investigation and management of suspected SARS-CoV-2 reinfections COVID-19: investigation and management of suspected SARS-CoV-2 reinfections - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional (...) cookies You can at any time. Hide this message Show or hide search Search on GOV.UK Search Menu National lockdown: stay at home Check what you need to do Guidance COVID-19: investigation and management of suspected SARS-CoV-2 reinfections Steps for investigating and managing individuals who are suspected to be reinfected with SARS-CoV-2. From: Published: 15 March 2021 Applies to: England Documents HTML Details This guidance is for clinicians and infection specialists. It provides details

2021 Public Health England

6. SARS-CoV-2 infection, COVID-19 and timing of elective surgery

SARS-CoV-2 infection, COVID-19 and timing of elective surgery SARS-CoV-2 infection, COVID-19 and timing of elective surgery A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Centre for Perioperative Care, Federation of Surgical Specialty Associations, Royal College of Anaesthetists, Royal College of Surgeons of England K. El-Boghdadly, 1,2 T. M. Cook, 3,4 T. Goodacre, 5,6 J. Kua, 7 L. Blake, 8 S. Denmark, 9 S. McNally, 10,11 N. Mercer, 12,13 S. R (...) of Surgical Specialty Associations, Glasgow, UK Correspondence: elboghdadly@gmail.com Twitter: @elboghdadly; @doctimcook; @scarlettmcnally @NigelMercer @rmoonesinghe ORCID: KE, 0000-0002-9912-717X; TMC, 0000-0002-3654-497X; LB, 0000-0002-8234-8611 Keywords: COVID-19; SARS-CoV-2; surgery; timing; complications Short title: SARS-CoV-2 infection and timing of surgery 3 Summary The scale of the COVID-19 pandemic means that a significant number of patients who have previously been infected with SARS-CoV-2

2021 ICM Anaesthesia COVID-19

7. Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2)

Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you

2021 Health Canada - drugs and medical devices

8. Efficacy and Safety Data of Treatments for Novel Coronavirus Pneumonia (SARS-Cov-2): A Systematic Review and Network Meta-Analysis of Randomized Trials Full Text available with Trip Pro

, Université Gamal Abdel Nasser de Conakry, Service de Pneumo-Phtisiologie, CHU Conakry, Hôpital National Ignace Deen de Conakry, Guinea Abstract To date, there is no definite effective treatment for the novel coronavirus (SARS-CoV-2) pandemic. To compare and rank SARS-Cov-2 treatment according to their efficacy and safety. Using the terms Covid-19 or SARS-CoV-2 and treatment , a literature search was performed from MEDLINE, GOOGLE, and CENTRAL databases until July 01, 2020. Randomized clinical trials (...) Efficacy and Safety Data of Treatments for Novel Coronavirus Pneumonia (SARS-Cov-2): A Systematic Review and Network Meta-Analysis of Randomized Trials Efficacy and Safety Data of Treatments for Novel Coronavirus Pneumonia (SARS-Cov-2): A Systematic Review and Network Meta-Analysis of Randomized Trials | | ISSN: 2474-3658 Table of Contents - - - - - - - - - - - - - - - - - - - Citation Diallo A, Traoré M, Carlos-Bolumbu M, Diallo MH, Diallo BD (2020) Efficacy and Safety Data of Treatments

2020 Journal of Infectious Diseases and Epidemiology

9. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries Full Text available with Trip Pro

of this project. Competing interests: The authors have declared that no competing interests exist. Introduction The novel coronavirus (SARS-CoV-2; 2019-nCoV; COVID-19) pandemic is a global crisis. As of April 10 th 2020, there were over 1.5 million confirmed cases of whom over 92,000 have died [ ]. In the absence of a vaccine or treatment with proven efficacy, limiting human-to-human transmission is critical [ – ]. Self-isolation (or self-quarantine) is an effective global strategy for limiting transmission (...) The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries ') Advertisement Publish Submissions Policies Manuscript Review and Publication Submit Your Manuscript Discover a faster, simpler path to publishing

2020 PloS one

10. The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review Full Text available with Trip Pro

The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review | medRxiv Search for this keyword The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic (...) , Cardiff, CF10 4PL, United Kingdom Peter Groves 1 Health Technology Wales, Life Sciences Hub, 3 Assembly Square , Cardiff, CF10 4PL, United Kingdom STRUCTURED ABSTRACT Objectives We undertook a rapid systematic review with the aim of identifying evidence that could be used to answer the following research questions: (1) What is the clinical effectiveness of tests that detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to inform COVID-19 diagnosis? (2) What

2020 Cold Spring Harbor Laboratory

11. The Effectiveness of Tests to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review Full Text available with Trip Pro

The Effectiveness of Tests to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review The Effectiveness of Tests to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review by David Jarrom, Lauren Elston, Jennifer Washington, Matthew Prettyjohns, Kimberley Cann, Susan Myles, Peter Groves :: SSRN Share: Permalink Using these links will ensure access (...) to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review 67 Pages Posted: 11 Aug 2020 Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Abstract Background: In response to the emergence of the SARS-CoV-2 virus and the subsequent COVID-19 pandemic, a number of tests have been rapidly developed to assist with COVID-19

2020 SSRN Electronic Journal

12. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Full Text available with Trip Pro

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Retrospective case series.Seven hospitals in Zhejiang province, China.62 patients admitted to hospital with laboratory confirmed SARS (...) time from exposure to onset of illness was 4 days (interquartile range 3-5 days), and from onset of symptoms to first hospital admission was 2 (1-4) days.As of early February 2020, compared with patients initially infected with SARS-Cov-2 in Wuhan, the symptoms of patients in Zhejiang province are relatively mild.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2020 BMJ

13. SARS-CoV-2 viral load and the severity of COVID-19 Full Text available with Trip Pro

SARS-CoV-2 viral load and the severity of COVID-19 SARS-CoV-2 viral load and the severity of COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website SARS-CoV-2 viral load and the severity of COVID-19 March 26, 2020 Carl Heneghan, Jon Brassey, Tom Jefferson Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford (...) The initial dose of virus and the amount of virus an individual has at any one time might worsen the severity of COVID 19 disease. Viral load is a measure of the number of viral particles present in an individual. Higher SARS-CoV-2 viral loads. might worsen outcomes, and data from China suggests the with more severe disease. The amount of virus exposure at the start of infection – the infectious dose – may increase the severity of the illness and is also. linked to a higher viral load Healthcare workers

2020 Oxford COVID-19 Evidence Service

14. Is there any significant difference in sensitivity of COVID-19 virus (SARS-CoV-2) tests based on swabs from oropharyngeal (OP) vs nasopharyngeal (NP) sampling vs both?

recommending collecting only nasopharyngeal swabs (NP), not NP and oropharyngeal swabs (OP). However, OP would be easier to do without training than NP, so one question is whether there is a significant difference in sensitivity between the two methods or using them in combination. SEARCH STRATEGY Search terms: COVID-19, SARS-CoV-2, wuhan coronavirus, 2019-nCoV, 2019nCoV, nasopharyngeal, oropharyngeal, swab, diagnosis, diagnostic, test, sensitivity Databases: PubMed, Embase, Web of Science, Scopus (...) Is there any significant difference in sensitivity of COVID-19 virus (SARS-CoV-2) tests based on swabs from oropharyngeal (OP) vs nasopharyngeal (NP) sampling vs both? Comparative accuracy of oropharyngeal and nasopharyngeal swabs for diagnosis of COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Comparative accuracy of oropharyngeal and nasopharyngeal swabs for diagnosis of COVID-19 March 26

2020 Oxford COVID-19 Evidence Service

15. COVID-19: Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2)?

and the effect of the weather on the host. The weather effect is minimal, and all estimates are subject to significant biases reinforcing the need for robust public health measures. BACKGROUND Most countries across the globe have now implemented a suite of strategies to reduce transmission of the novel coronavirus (2019-nCoV) and mitigate the effects of the COVID-19. The virus is known to have originated in the port city of Wuhan, in the central Hubei province, China. At the time when the first case (...) COVID-19: Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2)? Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2) - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2) Jon Brassey, Carl Heneghan, Kamal R. Mahtani, Jeffrey K. Aronson On behalf of the Oxford COVID-19

2020 Oxford COVID-19 Evidence Service

16. COVID-19: Spreading SARS-CoV-2 through ocular fluids

COVID-19: Spreading SARS-CoV-2 through ocular fluids Maximising mobility in the elderly when isolated with COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Maximising mobility in the elderly when isolated with COVID-19 JAMIE HARTMANN-BOYCE 20/03/2020 On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences

2020 Oxford COVID-19 Evidence Service

17. Covid-19: Immunity after SARS-CoV-2 infection

Covid-19: Immunity after SARS-CoV-2 infection Immunity after SARS-CoV-2 infection - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Immunity after SARS-CoV-2 infection Order Download: Key message The findings in this memo are based on rapid searches in PubMed, EMBASE and two pre-print databases. One researcher went through all search (...) on the severity of SARS-CoV-2 infection? Seroconversion rate and timing do not appear to differ between patients with mild to severe/critical COVID 19 infection. Studies of asymptomatic cases are however lacking. Can antibodies be transmitted from women infected with SARS-CoV-2 to the fetus via placenta and thus confer immunity in the newborn? Results from one small study suggest that antibodies from SARS-CoV-2 infected women may be transmitted to the foetus during pregnancy, but the evidence is uncertain

2020 Norwegian Institute of Public Health

18. Current epidemiology and guidance for COVID-19 caused by SARS-CoV-2 virus, in children: March 2020

-CoV-2 virus, in children: March 2020 Posted: Mar 25 2020 The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) Nicole Le Saux, Canadian Paediatric Society, The emergence in December 2019 of COVID-19, caused by a novel coronavirus, and its subsequent spread around the world, led the World Health Organization to declare a pandemic on March 11, 2020 (...) Current epidemiology and guidance for COVID-19 caused by SARS-CoV-2 virus, in children: March 2020 Current epidemiology and guidance for COVID-19 caused by SARS-CoV-2 virus, in children: March 2020Current epidemiology and guidance for COVID-19 caused by SARS-CoV-2 virus, in children: March 2020 | Canadian Paediatric Society A home for paediatricians. A voice for children and youth. Current: Current epidemiology and… Practice Point Current epidemiology and guidance for COVID-19 caused by SARS

2020 Canadian Paediatric Society

19. Covid-19: Contact based transmission of SARS-CoV-2 - a rapid review

. April 2020) Restricted to SARS-CoV-2 and studies published after 1. December 2019. ((((Coronavirus[mh] OR "Coronavirus Infections"[mh] OR "corona virus"[tw] OR coro- navirus*[tw] OR coronovirus*[tw]) AND (novel[tw]OR 2019[tw] OR Wuhan[tw] OR Huanan[tw])) OR "covid-19"[nm] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "COVID-19"[tw] OR COVID19[tw] OR CORVID-19[tw] OR CORVID19[tw] OR "coronavirus 2"[tw] OR "corona virus 2"[tw] OR nCoV[tw] OR 2019nCoV[tw] OR "SARS-CoV-2"[tw] OR "SARS-CoV2 (...) Covid-19: Contact based transmission of SARS-CoV-2 - a rapid review COVID-19-EPIDEMIC : Contact based transmission of SARS-CoV-2 – a rapid review me moTitle Contact based transmission of SARS-CoV-2 Norwegian title Kontaktsmitte av SARS-CoV-2 Institution Norwegian Institute of Public Health Responsible Camilla Stoltenberg, Director General Authors Brurberg, KG. Department Director, Norwegian Institute of Public Health ISBN 978-82-8406-079-8 Memo April – 2020 Publication type Rapid Review, Covid

2020 Norwegian Institute of Public Health

20. Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic

Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic (April 1, 2020) | The National Academies Press Menu Menu ( 2020 ) View Cover ( 2020 ) × Embed Book Widget Copy the HTML code below to embed this book in your own blog, website, or application. Custom Size: × × Close What is a prepublication? An uncorrected copy, or prepublication (...) , public health, public health preparedness and response, biological sciences, clinical care and crisis standards of care, risk communication, and regulatory issues. This publication responds to questions concerning the possibility that the SARS-Cov-2 virus could be spread by conversation, in addition to sneeze/cough-induced droplets. Suggested Citation National Research Council. 2020. Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic (April 1

2020 Covid-19 Ad hoc papers

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>